GNFT Stock Analysis: Genfit S.A. | PA
Biotechnology | PA, France | Market Cap: 509m EUR | 12M Return: 213.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.63M
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: under 40 is mostly noise, over 50 gets interesting, and over 70 is strong.
Genfit S.A. is a late-stage biopharmaceutical company founded in 1999 and headquartered in Loos, France, focused on discovering and developing therapeutic drug candidates and diagnostic solutions for metabolic and liver-related diseases. Its lead clinical asset, Elafibranor, is currently in a Phase III trial for primary biliary cholangitis (PBC). Beyond Elafibranor, the companys pipeline spans multiple programs at various stages of development, including the NIS4 diagnostic technology for nonalcoholic steatohepatitis (NASH), GNS561 (in Phase 1b/2a for cholangiocarcinoma), and earlier-stage candidates targeting conditions such as Urea Cycle Disorder, acute-on-chronic liver failure, and hyperammonemia.
Genfit operates a dual business model that combines drug development with diagnostic commercialization, exemplified by its licensing agreement with Labcorp to commercialize NASHnext, a blood-based molecular diagnostic test for NASH and fibrosis. The company has also partnered with Genoscience Pharma to co-develop and commercialize GNS561 for cholangiocarcinoma, indicating a reliance on strategic partnerships to advance and monetize its pipeline. As a small-cap player in the Health Care sector, Genfits value proposition is closely tied to the outcomes of its late-stage clinical trials, particularly Elafibranors Phase III results in PBC.
- Elafibranor Phase III PBC trial results pending
- NASHnext diagnostic revenues scale via Labcorp partnership
- Cash burn and runway pressure amid pipeline advancement
| Net Income: -86.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -26.51 > 1.0 |
| NWC/Revenue: 106.7% < 20% (prev 24.90%; Δ 81.75% < -1%) |
| CFO/TA -0.16 > 3% & CFO -25.1m > Net Income -86.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.9m) vs 12m ago 0.32% < -2% |
| Gross Margin: 24.60% > 18% (prev 99.58%; Δ -74.98% > 0.5%) |
| Asset Turnover: 43.63% > 50% (prev 46.68%; Δ -3.06% > 0%) |
| Interest Coverage Ratio: -10.32 > 6 (EBIT TTM -56.9m / Interest Expense TTM 5.51m) |
| A: 0.46 (Total Current Assets 144.3m - Total Current Liabilities 72.3m) / Total Assets 157.9m |
| B: -3.01 (Retained Earnings -475.4m / Total Assets 157.9m) |
| C: -0.37 (EBIT TTM -56.9m / Avg Total Assets 154.7m) |
| D: -0.13 (Book Value of Equity -23.6m / Total Liabilities 181.6m) |
| Altman-Z'' = -9.43 = D |
| DSRI: 3.0 (Receivables 40.3m/7.56m, Revenue 67.5m/70.7m) |
| GMI: 4.05 (GM 99.58% / 24.60%) |
| AQI: 0.12 (AQ_t 0.04 / AQ_t-1 0.34) |
| SGI: 0.95 (Revenue 67.5m / 70.7m) |
| TATA: -0.39 (NI -86.0m - CFO -25.1m) / TA 157.9m) |
| Beneish M = 0.79 (Cap -4..+1) = D |
As of July 02, 2026, the stock is trading at EUR 10.60 with a total of 259,509 shares traded. Over the past week, the price has changed by -1.53%, over one month by +20.19%, over three months by +19.35% and over the past year by +213.64%.
Current recommended Stop Loss: 9.70 (which is 8.5% or 1.3 ATR below the current price).
Genfit S.A. has no consensus analysts rating.
P/E Forward = 7.5472
P/S = 7.7786
P/B = 7.5961
Revenue TTM = 67.5m EUR
EBIT TTM = -56.9m EUR
EBITDA TTM = -6.05m EUR
Long Term Debt = 105.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 42.9m EUR (from shortTermDebt, last quarter)
Debt = 154.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.92m
Net Debt = 53.5m EUR (calculated: Debt 154.6m - CCE 101.1m)
Enterprise Value = 562.5m EUR (509.0m + Debt 154.6m - CCE 101.1m)
Interest Coverage Ratio = -10.32 (Ebit TTM -56.9m / Interest Expense TTM 5.51m)
EV/FCF = -21.25x (Enterprise Value 562.5m / FCF TTM -26.5m)
FCF Yield = -4.71% (FCF TTM -26.5m / Enterprise Value 562.5m)
FCF Margin = -39.23% (FCF TTM -26.5m / Revenue TTM 67.5m)
Net Margin = -127.4% (Net Income TTM -86.0m / Revenue TTM 67.5m)
Gross Margin = 24.60% ((Revenue TTM 67.5m - Cost of Revenue TTM 50.9m) / Revenue TTM)
Gross Margin QoQ = -56.26% (prev none%)
Tobins Q-Ratio = 3.56 (Enterprise Value 562.5m / Total Assets 157.9m)
Interest Expense / Debt = 3.56% (Interest Expense 5.51m / Debt 154.6m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -42.6m (EBIT -56.9m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 2.00 (Total Current Assets 144.3m / Total Current Liabilities 72.3m)
Debt / Equity = -6.54 (negative equity) (Debt 154.6m / totalStockholderEquity, last quarter -23.6m)
Debt / EBITDA = -8.84 (negative EBITDA) (Net Debt 53.5m / EBITDA -6.05m)
Debt / FCF = -2.02 (negative FCF - burning cash) (Net Debt 53.5m / FCF TTM -26.5m)
Total Stockholder Equity = 48.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.58% (Net Income -86.0m / Total Assets 157.9m)
RoE = -176.0% (Net Income TTM -86.0m / Total Stockholder Equity 48.9m)
RoCE = -36.95% (EBIT -56.9m / Capital Employed (Equity 48.9m + L.T.Debt 105.0m))
RoIC = -34.08% (negative operating profit) (NOPAT -42.6m / Invested Capital 125.1m)
WACC = 7.31% (E(509.0m)/V(663.6m) * Re(8.72%) + D(154.6m)/V(663.6m) * Rd(3.56%) * (1-Tc(0.25)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 47.74 | Cagr: 0.17%
[DCF] Fair Price = unknown (Cash Flow -26.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 75.83 | Revenue CAGR: 83.34% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.19 | Chg30d=+232.08% | Revisions=+20% | GrowthEPS=+140.3% | GrowthRev=+33.9%
EPS next Year (2027-12-31): EPS=0.84 | Chg30d=+0.00% | Revisions=+20% | GrowthEPS=+340.5% | GrowthRev=+25.3%
[Analyst] Revisions Ratio: +20%